A review of cutaneous anthrax and its outcome.
Anthrax is still an endemic disease in some countries in the world and has become a re-emerging disease in western countries with recent intentional outbreak. The aim of this study was to review our clinical experience with cutaneous anthrax cases. From the patient's files, transmission of the diseases, clinical findings and severity of infection, treatment and outcome of patients were recorded. Twenty-two cases were diagnosed as cutaneous anthrax in the last 7 years. Of these cases, 10 cases were severe form of cutaneous anthrax, 10 cases were mild form and 2 cases were toxemic shock due to cutaneous anthrax. The incubation period was between 1 and 17 days. The main clinical characteristics of the cases with severe cutaneous anthrax were fever, hemorrhagic bullous lesions surrounded by an extensive erythema and edema, and leukocytosis. Two cases with toxemic shock had low systolic blood pressure, apathy and toxemic appearance, leukocytosis, hypoalbuminemia & hyponatremia. Penicillin G was given in 15 cases, amoxicillin in 4 and other antibiotics in 3 cases for 3-10 days. Skin lesion left deep tissue scar in 4 cases and were grafted. Physicians working in endemic areas and also in western countries should be aware of all clinical forms of anthrax.
Doganay
Mehmet
M
Department of Infectious Diseases, Faculty of Medicine, Erciyes University, Kayseri, Turkey. mdoganay@erciyes.edu.tr
Metan
Gokhan
G
Alp
Emine
E
D000293:Adolescent; D000328:Adult; D000658:Amoxicillin / Q000494:pharmacology / Q000627:therapeutic use; D000881:Anthrax / Q000175:diagnosis / Q000188:drug therapy; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D001408:Bacillus anthracis / Q000187:drug effects* / Q000302:isolation & purification; D002939:Ciprofloxacin / Q000494:pharmacology / Q000627:therapeutic use; D004318:Doxycycline / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010402:Penicillin G Procaine / Q000494:pharmacology / Q000627:therapeutic use; D017192:Skin Diseases, Bacterial; D016896:Treatment Outcome; D014421:Turkey; D055815:Young Adult
D000900:Anti-Bacterial Agents; D010402:Penicillin G Procaine; D002939:Ciprofloxacin; D000658:Amoxicillin; D004318:Doxycycline